Vietnam's life sciences industry is rapidly evolving from a manufacturing-focused healthcare market into one of Southeast Asia's most dynamic centres for biotechnology, pharmaceutical innovation and advanced medical research. Supported by government investment, international partnerships and expanding healthcare demand, the country's life sciences ecosystem is attracting increasing attention from global manufacturers, investors and research organisations.
While no single report measures the entire life sciences sector, IMARC Group estimates Vietnam's Life Science Tools Market alone reached US$712.2 million in 2025 and is forecast to grow to US$1.412 billion by 2034. When pharmaceuticals, biotechnology, diagnostics and clinical research are included, the broader commercial life sciences sector is estimated to be worth US$9–11 billion today and continues to expand rapidly.
Life sciences is increasingly recognised as a strategic industry supporting healthcare delivery, pharmaceutical manufacturing and biomedical innovation. The sector spans:
- Biotechnology
- Pharmaceutical manufacturing
- Biopharmaceuticals
- Laboratory technologies
- Molecular diagnostics
- Genomics
- Cell and gene therapies
- Clinical research
- Medical devices
- Laboratory informatics
- Artificial intelligence for healthcare
- Precision medicine
Several structural trends are driving growth across Vietnam.
Healthcare expenditure continues to rise as the country expands access to modern medical services and invests in new hospitals and specialist treatment centres. At the same time, Vietnam's ageing population and growing burden of chronic diseases are increasing demand for innovative medicines, diagnostics and medical technologies.
The government has also identified biotechnology and scientific innovation as priority industries within its long-term economic development strategy. Research universities, hospitals and public research institutes are expanding capabilities in molecular biology, genomics and biomedical engineering, while international pharmaceutical companies are increasing research collaborations and manufacturing investment.
Life science tools are becoming one of the fastest-growing areas within the sector. Modern laboratories increasingly rely on automated PCR systems, next-generation sequencing platforms, flow cytometers, digital pathology, advanced microscopy and AI-powered laboratory software to improve research productivity and diagnostic accuracy.
Clinical research is another rapidly expanding field. Vietnam offers a large and diverse patient population, an improving regulatory environment and increasing numbers of internationally accredited hospitals capable of participating in multinational clinical trials. This is attracting greater interest from pharmaceutical companies and contract research organisations seeking to expand research activity across Southeast Asia.
Artificial intelligence is beginning to transform the life sciences landscape. AI is supporting drug discovery, pathology, genomic analysis, laboratory automation and clinical trial optimisation, while cloud computing and advanced analytics are improving collaboration between hospitals, universities and industry partners.
Global investment is also accelerating. International pharmaceutical manufacturers continue to expand biologics production, vaccine development and advanced manufacturing technologies across Asia, while venture capital is increasingly supporting Vietnamese biotechnology start-ups specialising in genomics, precision diagnostics and digital healthcare.
Leading companies active across Vietnam's life sciences ecosystem include Roche, Thermo Fisher Scientific, Abbott, Siemens Healthineers, Danaher, Merck KGaA, Pfizer, AstraZeneca, Novo Nordisk, GE HealthCare, Illumina, QIAGEN, Bio-Rad Laboratories, Agilent Technologies and an expanding number of domestic biotechnology innovators.
As Vietnam strengthens its research capability, modernises healthcare infrastructure and expands pharmaceutical manufacturing, the country's life sciences sector is expected to become one of the most attractive investment destinations in Southeast Asia. For manufacturers of laboratory technologies, biotechnology solutions, diagnostics, pharmaceuticals, research equipment and digital health platforms, Vietnam offers substantial opportunities for long-term growth across both clinical and research markets.